Citation Impact
Citing Papers
Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack
2014 Standout
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance
2018 Standout
Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report
2016 Standout
The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe
2016
Can discrete event simulation be of use in modelling major depression?
2006
Evaluation and Management of Anal Intraepithelial Neoplasia in HIV-Negative and HIV-Positive Men Who Have Sex with Men
2010
Global patterns and trends in colorectal cancer incidence and mortality
2016 Standout
Verification problems in diagnostic accuracy studies: consequences and solutions
2011
Systematic review and economic modelling of effectiveness and cost utility of surgical treatments for men with benign prostatic enlargement
2008
American Gastroenterological Association Institute Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug Therapy
2014
The cost of health care for children and adults with sickle cell disease
2009
A pharmacist-led information technology intervention for medication errors (PINCER): a multicentre, cluster randomised, controlled trial and cost-effectiveness analysis
2012
Burden of liver diseases in the world
2018 Standout
Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide
2014 Standout
Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study
2017 Standout
Conflict of interest in economic analyses of aromatase inhibitors in breast cancer: a systematic review
2010
Modeling Good Research Practices—Overview: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1
2012 Standout
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
2017 Standout
User Satisfaction With Telehealth
2015
SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials
2013 Standout
Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation
2015 Standout
Healthcare utilization and expenditures for low income children with sickle cell disease
2008
Poor Recognition of Risk Factors for Hepatitis B by Physicians Prescribing Immunosuppressive Therapy: A Call for Universal Rather than Risk-Based Screening
2015
The REDCap consortium: Building an international community of software platform partners
2019 Standout
American Gastroenterological Association Institute Technical Review on Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug Therapy
2014
Conceptualizing a Model: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-2
2012
Colorectal cancer
2013 Standout
The stomach in health and disease
2015
Performance of screening tests for child physical abuse in accident and emergency departments
2008
Burden and consequences of child maltreatment in high-income countries
2008 Standout
Colorectal cancer
2019 Standout
Mechanisms of NAFLD development and therapeutic strategies
2018 Standout
Antithrombotic Therapy for VTE Disease
2012 Standout
Global cancer statistics
2011 Standout
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
2010 Standout
A role of PIEZO1 in iron metabolism in mice and humans
2021 StandoutNobel
Cost of illness studies in rheumatic diseases
2002
Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial
2010
State-Transition Modeling: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3
2012
Interventions to improve antibiotic prescribing practices for hospital inpatients
2013 Standout
Lost Productive Time and Cost Due to Common Pain Conditions in the US Workforce
2003 Standout
Application of an electronic Frailty Index in Australian primary care: data quality and feasibility assessment
2018
Model Transparency and Validation: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7
2012
Cost-effectiveness of Colorectal Cancer Screening
2011
A new framework for developing and evaluating complex interventions: update of Medical Research Council guidance
2021 Standout
Emerging Biological Principles of Metastasis
2017 Standout
Sickle-cell disease
2010 Standout
Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis
2009 Standout
Dynamic Transmission Modeling: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-5
2012
Homophily and co-occurrence patterns shape randomized trials agendas: illustration in antifungal agents
2011
A taxonomy of model structures for economic evaluation of health technologies
2006
Frailty: implications for clinical practice and public health
2019 Standout
Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement
2015 Standout
Primary and Secondary Prevention of Cardiovascular Disease
2012
Pharmacoeconomic Analyses Using Discrete Event Simulation
2005
Impact of an informed choice invitation on uptake of screening for diabetes in primary care (DICISION): randomised trial
2010
Does tumour dormancy offer a therapeutic target?
2010
Hepatitis B virus reactivation in patients with solid tumors receiving systemic anticancer treatment
2016
Lesbian, Gay, Bisexual, and Transgender–Related Content in Undergraduate Medical Education
2011 Standout
Cost-effectiveness of Magnetic Resonance (MR) Imaging and MR-guided Targeted Biopsy Versus Systematic Transrectal Ultrasound–Guided Biopsy in Diagnosing Prostate Cancer: A Modelling Study from a Health Care Perspective
2013
Cervical cancer
2019 Standout
Motor recovery after stroke: a systematic review
2009 Standout
Haemoglobinopathies in Europe: health & migration policy perspectives
2014
Value of composite reference standards in diagnostic research
2013
Hepatitis B Virus Reactivation and Prophylaxis During Solid Tumor Chemotherapy
2015
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
2023 Standout
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
2017 Standout
A prospective randomised controlled trial and economic modelling of antimicrobial silver dressings versus non-adherent control dressings for venous leg ulcers: the VULCAN trial
2009
Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration
2015 Standout
Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
2018 Standout
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2019 Standout
Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease
2015
International recommendations for national patient safety incident reporting systems: an expert Delphi consensus-building process
2016
A Perspective on Cancer Cell Metastasis
2011 StandoutScience
Endovenous thermal ablation for healing venous ulcers and preventing recurrence
2013 StandoutNobel
Model Transparency and Validation
2012
Decision aids for people facing health treatment or screening decisions
2017 Standout
A Review on Iron Chelators in Treatment of Iron Overload Syndromes.
2016
Framework for the development and evaluation of complex interventions: gap analysis, workshop and consultation-informed update
2021
Presenting quantitative information about decision outcomes: a risk communication primer for patient decision aid developers
2013
Randomised clinical trial, observational study and assessment of cost-effectiveness of the treatment of varicose veins (REACTIV trial)
2006
The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations
2015 Standout
Low Rates of Hepatitis B Virus Screening at the Onset of Chemotherapy
2012
Systematic review of compression following treatment for varicose veins
2015 StandoutNobel
Dynamic Transmission Modeling
2012
Screening for hyperglycaemia in pregnancy: a rapid update for the National Screening Committee
2010 StandoutNobel
Accounting for Methodological, Structural, and Parameter Uncertainty in Decision-Analytic Models
2011
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
Physical Activity/Exercise and Diabetes: A Position Statement of the American Diabetes Association
2016 Standout
Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease
2017 Standout
Quantifying the Added Value of a Diagnostic Test or Marker
2012
Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months
2018
Exercise and Type 2 Diabetes
2010
Decision Making in Health and Medicine: Integrating Evidence and Values
2001
Conceptualizing a Model
2012
Industry sponsorship and research outcome
2017 Standout
SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials
2013 Standout
Comparison of MR/Ultrasound Fusion–Guided Biopsy With Ultrasound-Guided Biopsy for the Diagnosis of Prostate Cancer
2015 Standout
The Measurement of Observer Agreement for Categorical Data
1977 Standout
Early high-dose lipid-lowering therapy to avoid cardiac events: a systematic review and economic evaluation
2009
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2019 Standout
Works of Jonathan Karnon being referenced
Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
2006
Selecting a decision model for economic evaluation: a case study and review
1998
A systematic review of economic analyses of telehealth services using real time video communication
2010
Calibrating Models in Economic Evaluation
2010
The Value of Value of Information
2010
Model Parameter Estimation and Uncertainty: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-6
2012
Option appraisal of population-based colorectal cancer screening programmes in England
2006
Trends in healthcare incident reporting and relationship to safety and quality data in acute hospitals: results from the National Reporting and Learning System
2009
Alternative decision modelling techniques for the evaluation of health care technologies: Markov processes versus discrete event simulation
2002
Cost Effectiveness of Extended Adjuvant Letrozole in Postmenopausal Women after Adjuvant Tamoxifen Therapy
2006
A trial-based cost-effectiveness analysis of letrozole followed by tamoxifen versus tamoxifen followed by letrozole for postmenopausal advanced breast cancer
2003
Calibrating Models in Economic Evaluation
2010
Cost-Effectiveness of Letrozole Versus Tamoxifen as Initial Adjuvant Therapy in Hormone Receptor–Positive Postmenopausal Women with Early-Stage Breast Cancer
2007
Cost-Effectiveness of Letrozole in the Extended Adjuvant Treatment of Women with Early Breast Cancer
2006
A review and critique of modelling in prioritising and designing screening programmes
2007
Cost-utility analysis of screening high-risk groups for anal cancer
2008
A Stochastic Economic Evaluation of Letrozole versus Tamoxifen as a First-Line Hormonal Therapy
2003
Feasibility, acceptability and diagnostic test accuracy of frailty screening instruments in community-dwelling older people within the Australian general practice setting: a study protocol for a cross-sectional study
2017
The Importance of High-Quality Evidence of the Long-Term Impact of Nonfatal Events Used in Randomized Controlled Trials: A Case Study of Prasugrel
2011
Model‐based cost‐effectiveness analysis of interventions aimed at preventing medication error at hospital admission (medicines reconciliation)
2009
A cost-utility analysis of clopidogrel in patients with non-ST-segment-elevation acute coronary syndromes in the UK
2005
Screening for sickle cell and thalassaemia in primary care: a cost-effectiveness study
2011
Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective
2007
Modeling using Discrete Event Simulation: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-4
2012
Lifetime treatment costs of β-thalassaemia major
1999
The effects of neonatal screening for sickle cell disorders on lifetime treatment costs and early deaths avoided: a modelling approach
2000
Cost-utility analysis of deferasirox compared to standard therapy with desferrioxamine for patients requiring iron chelation therapy in the United Kingdom
2008
Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective
2007
The role of modelling in prioritising and planning clinical trials
2003
Model Parameter Estimation and Uncertainty Analysis
2012
Economic evaluation alongsiden-of-1 trials: getting closer to the margin
2001
Antenatal and neonatal haemoglobinopathy screening in the UK: review and economic analysis.
1999
Liquid-based cytology in cervical screening: an updated rapid and systematic review and economic analysis
2004
Modeling Using Discrete Event Simulation
2012
Cost-Effectiveness of Universal Hepatitis B Virus Screening in Patients Beginning Chemotherapy for Solid Tumors
2011